Nurix Therapeutics, Inc. (NRIX) Stock

Nurix Therapeutics, Inc. (NRIX) is a Healthcare stock trading at $17.53 (as of 2026-06-18), with a market capitalization of $1.84B and a trailing P/E of -5.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Nurix Therapeutics, Inc. is a biopharmaceutical company that discovers, develops, and commercializes small-molecule therapies for cancer and immune disorders. Its pipeline includes BTK degraders (NX-2127 and NX-5948) and a CBL-B inhibitor for immuno-oncology (NX-1607), along with NX-0255 for ex vivo use in adoptive T-cell therapy and DeTIL-0255 for gynecologic cancers.

Valuation — source: SEC EDGAR (first-party)
Price	$17.53
Market Cap	$1.84B
P/E Ratio	-5.6
EV / EBITDA	-5.8
Price / Book	3.82
Price / Sales	25.59
DCF Value (model)	$-41.21
DCF Upside vs Price	-335.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$83.98M
Net Margin	-314.9%
Return on Equity	-61.4%
Current Ratio	6.01
Revenue Growth (YoY)	2.2%
EPS Growth (YoY)	9.3%
FCF Growth (YoY)	43.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	4.86 (safe)

Valuation vs Sector & Industry
Stock P/E	-5.6
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-126.7%
vs Industry	-132.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($138.35M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Arthur T. Sands
Employees	286
Country	US
IPO Date	2020-07-24

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.